2Lapraik C, Watts R, Bacon P, et al. BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis [J]. Rheumatology ,2007,46 (10) : 1615-1616.
3Serpieri N. Cyclophosphamide in ANCA associated vasculitis:contin-uous oral vs pulse therapy[J]. G Ital Nefrol,2010,27 (6) :566.
4Levine SM. Pulse versus daily oral cyclophosphamide in ANCA-asso- ciated vasculitis[J]. Ann Intern Med ,2010,152 ( 1 ) :65.
5Adu D, Pall A, Luqmani R, et al. Controlled trim of pulse versus con- tinuous prednisolone and cyclophosphamide in the treatment of sys- temic ANCA-associated vasculitis [J]. Qjm, 1997,90 (6) :401.
6Gayrand M, Guillevin L, Cohen P, et al. Treatment of good-prognosis polyarteritis nodosa and Churg-Strauss syndrome:comparison of ster- oids and oral or pulse cyclophosphamide in 25 patients. French Co- operative Study Group for Vasculitides [J]. Rheumatology, 1997,36 (12) : 1290-1297.
7Guillevin L, Cordier JF, Lhote F, et al. A prospective, muhicenter, randomized trial comparing steroids and pulse cyclophosphamide ver- sus steroids and oral cyclophosphamide in the treatment of general- ized Wegener's granulomatosis [J]. Arthritis & Rheumatism, 1997, 40(12) :2187-2198.
8Haubitz M, Schellong S, Gbel U, et al. Intravenous pulse administra- tion of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody - associated vasculitis and renal involvement : a prospective, randomized study [J]. Arthritis & Rheu- matism, 1998,41 (10) :1835-1844.
9de Groot K, Harper L, Jayne DR, et al. Pulse versus daily oral cyclo- phosphamide for induction of remission in antineutrophil cytoplasmic antibody--associated vasculitis: a randomized trial[J]. Annals of in- ternal medicine,2009,150 (10) :670.
10Rihova Z,Jancova E ,Merta M,et al. Daily oral versus pulse intrave- nous cyclophosphamide in the therapy of ANCA-associated vasculi- tis-preliminary single center experience[J]. Prague Med Rep ,2004, 105(1) :64-68.
